Health is a global health concept proposed in response to the development of the times, social needs and changes in the disease spectrum, and under the impetus of multiple favorable factors such as policy guidance, public health needs, and health awareness improvement, the development of China's health industry is continuing to improve
.
According to incomplete statistics, the market size of the large health industry has reached 7 trillion yuan in 2020, and according to the current development trend, it is predicted that the market will exceed 8 trillion yuan
by 2022.
In the trillion-dollar health market, pharmaceutical companies are also increasing their layout (Image source: Pharmaceutical Network)
At a time when the big health market is expanding and the concept of health has been deeply rooted in the hearts of the people, many domestic companies are also focusing on the field of big health and increasing their layout
.
Among them, pharmaceutical companies are undoubtedly active players
in this track.
In recent years, a large number of pharmaceutical companies are actively deploying the big health industry by increasing R&D investment and cooperation, and striving to seize the track
.
For example, on November 11, Tailong Pharmaceutical issued a capital increase announcement, intending to increase the capital of Tailong Health by 220 million yuan in cash (including an increase of 29.
2 million yuan in registered capital and an increase in capital reserve of 191 million yuan).
It is worth mentioning that Tailong Pharmaceutical also intends to take Tailong Health as a limited partner, and establish a new wholly-owned subsidiary Hangzhou Tailong Jintang Enterprise Management Co.
, Ltd.
(tentative name) as the general partner, and jointly invest and establish Longhua Pharmaceutical Industry Fund
with Zhengzhou High-tech Industry Investment Group Co.
, Ltd.
, an indirect controlling shareholder of the company, and its wholly-owned subsidiary, Zhengzhou High-tech Industry Investment Fund Co.
, Ltd.
The size of the fund is 400 million yuan, of which Tailong Health subscribed and contributed 216 million yuan, accounting for 54% of the total size of the fund; Hangzhou Tailong Jintang Enterprise Management Co.
, Ltd.
subscribed and contributed 4 million yuan, accounting for 1%
of the total size of the fund.
In response to investors' questions on the interactive platform on November 28, Huasen Pharmaceutical said that the company's big health products are in the market promotion period, including the nutritional meal replacement companion series, the health tea series, and the recently launched Yanpinsen series
.
It is reported that Huasen Pharmaceutical has already begun to cut into the special medical food track to lay out the field of
health industry.
It completed the construction of special medical food production line and hardware equipment in June this year, and is expected to build the first special medical food production base
in Sichuan-Chongqing area.
On the evening of November 7, Puli Pharmaceutical issued an announcement that due to the company's business development needs, in order to realize the company's business layout based on life and health, the company intends to use its own funds to invest in the establishment of a wholly-owned subsidiary Zhejiang Puli Health Technology Co.
, Ltd.
, with a registered capital of 10 million yuan.
.
.
The scope of the big health industry is broad, involving the upper and lower industrial chains are also very broad, including nutritional health food, health care equipment, leisure and health care services, etc.
, so the industry believes that in the context of today's big health industry facing a good development opportunity, the pharmaceutical machinery and equipment industry may also usher in more opportunities
.
According to the author's understanding, at present, some pharmaceutical equipment companies have already extended their tentacles to the large health industry
.
For example, based on the needs of enterprise planning and development, Canaan Technology launched the construction
of the Canaan Health Intelligent Industrial Park project.
The project will introduce 7 advanced intelligent production lines, form an annual production capacity of 4,000 sets of high-end intelligent medical equipment, build digital workshops, headquarters buildings, R&D centers and workers' homes, integrate digital management, scientific and technological research and development, intelligent manufacturing, technology incubation and other functions, belonging to the "500 billion" investment project of Zhejiang Province and the "152 Project" project
of Zhejiang Province.
In addition, the relevant person in charge also publicly stated that in the future, in addition to continuing to cultivate the pharmaceutical equipment and intelligent logistics industry and striving to become the international mainstream pharmaceutical equipment intelligent factory overall solution provider, Canaan Technology will further increase investment in the field of general health, accelerate product launch, strengthen close cooperation with leading enterprises in the industry, increase market development efforts, and gradually promote
the in-depth promotion of the big health industry based on existing customers.
Chutian Technology also plans to invest RMB 100 million in cash and other professional investment institutions to establish Changsha Biomedicine and Life Sciences No.
1 Private Equity Fund, which mainly invests in upstream and downstream related industries of the biomedical and life science industry chain (including but not limited to biomedicine, pharmaceutical equipment and core parts supply chain, medical equipment and consumables, medical services and general health, etc.
).
In addition, Hunan Qianshan Chronic Disease Health Management Co.
, Ltd.
, a subsidiary of Qianshan Yaoji Holdings, has already released a series of big health products in early 2017, taking a big step
towards entering the field of precision medicine.
It is worth noting that with the continuous development of the big health industry, higher requirements
will be put forward for the production quality and efficiency of pharmaceutical machinery and equipment.
In the face of new market demand, the industry believes that what pharmaceutical machinery and equipment companies need to do is to move forward bravely and continue to redouble their efforts in "quality" and "quantity" to meet the needs of
diversified markets.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
